Why This Matters The dose-dependent distinction highlights an important clinical insight: For obesity management, the upper dose range (812 mg) is likely to dominate
Although 95% of NAFLD patients have clinically overt metabolic abnormalities, about 5% have no cardiometabolic risk (CMR) factors, despite having hepatic steatosis [15]
There may be some evidence, though questionable, that active ingredients like berberine and green tea might curb cravings and reduce appetite a bit , but the effects are not dramatic enough for this to be an FDA-approved strategy. In other words, the patches are likely much ado about nothing
(2023) Anti-obesity medication use for adolescent metabolic and bariatric surgery patients: a systematic literature review
Retatrutide refers to a peptide known as LY3437943, which acts on three receptors: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R)
The observations here from both the tri-agonist and coagonist treatments are interesting, as numerous studies have indicated that GIPR activation results in weight gain, not weight loss